Biotech

0 312
Cidara Therapeutics Inc CDTX Stock News

Cidara Therapeutics Inc (NASDAQ: CDTX)

Cidara Therapeutics is having an overwhelmingly rough start to the trading session today, and for good reason. Unfortunately, the company reported results from a recent Phase 2 trial, and those results weren’t up to par. Below, we’ll talk about what we’re seeing from the stock, the results that were reported, and what we can expect from CDTX ahead.





What We’re Seeing From CDTX

As mentioned above, Cidara Therapeutics is having an incredibly disappointing start to the trading session today. When the opening bell rang, the stock was already trading incredibly low thanks to the early morning data release. Since the bell, the stock has maintained losses. At the moment (9:50), CDTX is trading at $7.25 per share after a loss of $4.45 per share or 38.08% thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the declines on CDTX. As soon as we received the alert, the CNA Finance team started digging to see what was causing the movement. It didn’t take long to uncover the story. Unfortunately, the company missed the primary endpoint of a recent trial.




The trial was a controlled Phase 2 trial known as RADIANT During the trial Cidara Therapeutics was assessing the efficacy of echinocandin antifungal CD101 in women with moderate-to-severe acute VVC. Unfortunately, the efficacy trial showed that the treatment was not quite as effective as hoped. In a statement, Jeffrey Stein, Ph.D., President and CEO at CDTX, had the following to offer…

We are obviously disappointed with these results, which did not demonstrate the highly potent antifungal properties of CD101 against Candida we saw in preclinical animal models of VVC. While we believe that an improved topical formulation of CD101 could improve outcomes, at this time we have no plans for further development of CD101 topical in VVC…. We would like to thank the investigators and the patients who participated in this trial. This does not impact our development of CD101 IV for the treatment of Candidemia and invasive Candidiasis, for which animal models are well established and highly predictive of clinical outcomes.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CDTX. In particular, we’re interested in the company’s plans moving forward. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 3033
Peregrine Pharmaceuticals PPHM Stock News

Peregrine Pharmaceuticals (NASDAQ: PPHM)

Peregrine Pharmaceuticals is having an overwhelmingly strong day in the market today. When the trading session opened, the stock was already trading slightly in the green. However, as the trading session progressed, a good day quickly turned great. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to PPHM ahead.





What We’re Seeing From PPHM

As mentioned above, Peregrine Pharmaceuticals is having an incredibly strong day in the market today. After starting the session off slightly green, the stock quickly started to run for the top. After hitting a peak, it dipped a bit, but the gains are still incredible. At the moment (12:10), PPHM is trading at $0.60 per share after a gain of $0.16 per share (36.30%) thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on PPHM. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, the gains are the result of a data release.




Early this morning, Peregrine Pharmaceuticals released encouraging data from a proof-of-concept study it has been working on. The study surrounds the company’s cancer detection platform that’s based on cell-derived vesicles known as exosomes.

From the data release, we learned that the PPHM test was able to distinguish between healthy subjects and patients that had ovarian tumors. This was seen through levels of exosomes in plasma samples that contained phosphatidylserine. Investigators also proved the ability to distinguish between benign and malignant tumors. This was done based on an analysis of PS-positive exosome levels.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance will be watching PPHM incredibly closely. In particular, we’ll be watching the company’s work toward pushing this test to commercial stages. We’ll continue to follow the story and bring the news to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 664
Heat Biologics Inc HTBX Stock News

Heat Biologics Inc (NASDAQ: HTBX)

Heat Biologics is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. From there, we’ve seen some downward and some upward movement, but it’s clear that the stock is staying well away from the red. Below, we’ll talk about what we’re seeing from HTBX, why, and what we’ll be watching for ahead.





What We’re Seeing From HTBX

As mentioned above, Heat Biologics is having an incredibly strong day in today’s trading session. When the session started for the day, the stock was already trading on impressive gains. While we have seen a bit of downward movement since then, the stock is still holding onto impressive gains and is likely to stay in the green all day. At the moment (10:46), HTBX is trading at $0.99 per share after a gain of $0.03 per share or 4.19% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on HTBX. As soon as we received the alert, the CNA Finance team started working to see exactly what was causing the movement. It didn’t take long to dig up the story. The gains are the result of a presentation of clinical data.




Early this morning Heat Biologics announced that it has presented a poster of its immunologic data from its 94 patient Phase 2 trial of HS-410 either alone or in combination with BCG in patients with non-muscle invasive bladder cancer. The presentation was given at the 2017 Genitourinary (GU) Cancers Symposium. For more information with regard to the presentation, click here.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HTBX. In particular, we’ll be watching for news with regard to the ongoing work the company is doing on HS-410. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 682
XBiotech Inc XBIT Stock News

XBiotech Inc (NASDAQ: XBIT)

XBiotech was off to a relatively normal day in the market today. When the trading session opened, the stock was trading slightly in the green. From there, it fell to the red, made it back to the green, and traded relatively flat throughout the morning. Nonetheless, minutes ago, things changed as the stock started to soar. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to XBIT ahead.





What We’re Seeing From XBIT

As mentioned above, today didn’t look like it was going to be a massively great day for XBiotech early on. At the opening bell, the stock was trading slightly in the green. From there, it quickly fell to the red before recovering. After making it back to the green, the stock was relatively flat throughout the day. At the moment (11:20), XBIT is trading at $13.11 per share after a gain of $0.91 per share or 7.46% thus far today.

Why The Stock Is Climbing

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on XBIT. As soon as we received the alert, the CNA Finance team started digging to see what was causing the movement. It didn’t take long to uncover the story. The gains are the result of clinical data that was released just minutes ago.




For some time now, XBiotech has been working on its Phase 2 Study of MABp1 for the treatment of Hidradenitis Suppurativa (HS). Minutes ago, the company announced that the study met the primary endpoint. As a result, excited investors are sending the stock toward the top.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on XBIT. In particular, we’ll be watching the news surrounding MABp1 and looking forward to the next steps the company will take to move this closer to FDA approval. Nonetheless, we’ll be watching the news closely and bringing the updates to you as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 616
Champions Oncology Inc CSBR Stock News

Champions Oncology Inc (NASDAQ: CSBR)

Champions Oncology, on Thursday, announced that the company has added new cohorts of PDX models to their existing TumorBank. These new models will expand CSBR’s product line in hepatocellular cancer, breast cancer, castrate resistant prostate cancer, head and neck cancer, AML, and non-small cell lung cancer PDX models.





With the addition of these PDX models, each with full clinical annotation, CSBR’s TumorBank portfolio is now provides greater than 900 clinically relevant patient-derived xenograft models.

CSBR Addresses Standard Of Care

Dr. Angela Davies, CMO at CSBR, commented on the addition of these new models. “Champions continues to invest in building new models that reflect the evolving standard of care to provide robust model cohorts for pre-clinical research and clinical trial simulation. Champions Medical Affairs and Clinical Operations infrastructure, designed to facilitate research collaborations, allows not only for new PDX model building but also supports building models co-clinically to maximize translational learning from early phase clinical trials.”

Champions continues to be aggressive in adding to its already impressive and relevant TumorBank. CSBR has added over 160 new and unique models during the past six months, which are intended to deliver a valuable and cost effective tool for the pharmaceutical industry in their pre-clinical and clinical drug development research.




An Emerging CSBR

CSBR is a unique company, engaged in the development of advanced technology solutions and services intended to offer a personalized development approach and use of oncology drugs. CSBR’s proprietary TumorGraft technology platform offers a novel approach to personalizing oncology care based upon the implantation of primary human tumors in immune deficient mice, which is then followed by by the propagation of engraftments in a manner that preserves the biological characteristics of the original human tumor. This, in turn, provides valuable information to allow clients a clear determination of a studied treatments efficacy potential.

The unique thesis behind CSBR is that the company is not affected by trial success or failure. The company is merely the conduit that allows the client to determine the appropriate and most logical course of action from pre-clinical to planned phase I trial applications.

As a contract provider, CSBR has no real skin in the game in regard to treatment efficacy, other than maintaining the ability to offer a 100% reliable model for a proposed study or treatment. This feature allows CSBR to benefit from the contract model, and at the same time eliminates the headline risk associated with trial or therapeutic results.

CSBR clients benefit tremendously from the CSBR’s TumorGraft technology, allowing those in the drug development space to significantly lower the cost of study and to increase the speed at which they can develop and deliver new drugs to market.

As always, CNA Finance will keep followers appraised of breaking news and further developments at CSBR.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 613
Akers Biosciences Inc AKER Stock News

Akers Biosciences Inc (NASDAQ: AKER)

Akers Biosciences is having a great start to today’s trading session. At the opening bell, the stock was already trading on dramatic gains. Throughout the first hour, we’ve seen a bit of movement in both directions, but the stock has been able to hold onto the strong gains. Below, we’ll talk about what we’re seeing from AKER, why, and what we’ll be watching for ahead.





What We’re Seeing From AKER

As mentioned above, Akers Biosciences is having an overwhelmingly strong day in the market today. When the trading session opened for the day, the stock was already trading on impressive gains. Since the open, the stock has seen some movement in both directions, but the gains have stuck around. At the moment (10:34), AKER is trading at $1.35 per share after a gain of $0.12 per share or 10.20% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on AKER. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the upward movement. It didn’t take long to dig up the story. The gains seem to be the result of a new United States patent that was announced this morning.




The patent announced will cover the design of Akers Biosciences’ disposable cartridge that contains the reagent for the detection of wellness markers. The reagent within the cartridge is analyzed using optical scanning technology after contact with the user’s exhaled breath sample, producing quantitative results through the Akers Wellness(TM) app on the users smartphone or tablet. In a statement, John J. Gormally, CEO at AKER had the following to offer…

We believe Akers Bio’s technology for rapidly analyzing biomarkers in breath condensate is ideally suited for tests in the expansive US health and wellness market. I am pleased that this latest patent has been allowed as it is essential that we have robust protection over our valuable intellectual property.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on AKER. In particular, we’re watching for further news with regard to the new patent, and what the company will do to bring the product to a profitable state. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 519
Neuralstem, Inc. CUR Stock News

Neuralstem, Inc. (NASDAQ: CUR)

Neuralstem is having an incredibly strong day in the market today. When the opening bell rang, the stock was already trading slightly in the green. From there, it took a few minutes to really grab onto some momentum before rocketing toward the top. Below, we’ll talk about what we’re seeing from CUR, why, and what we’ll be watching for ahead.





What We’re Seeing From CUR

As mentioned above, Neuralstem is having an incredibly strong start to today’s trading session. At the open, the stock was already trading slightly in the green. While it took a few minutes to get the momentum, the stock quickly rocketed to the top. At the moment (10:02), CUR is trading at $3.78 per share after a gain of $0.60 per share or 18.87% thus far today.

Why The Stock Is Making A Run For The Top

Our partners at Trade Ideas were the first to alert us of the gains on CUR, as is normally the case. As soon as the CNA Finance team got the alert, we started working to see what was causing the movement. In this particular case, there’s some fundamental news going around that’s really exciting investors.




Currently, Neuralstem is working on a Phase 2 clinical trial, from which data is expected to be released in the third fiscal quarter of 2017. Today however, the company announced the enrollment of its last patient. It is also expected that we will see the data from the clinical study ahead of schedule. Obviously, this is overwhelmingly positive news, which is leading to investor excitement.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on CUR. In particular, we’ll be watching the company’s progress through the ongoing Phase 2 clinical trial. Nonetheless, we’ll watch the news closely and be sure to bring you any updates as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 485
Brainstorm Cell Therapeutics Inc. BCLI Stock News

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)

Brainstorm Cell Therapeutics is having an incredibly strong start to today’s trading session. After a positive press release was offered, the stock climbed in the pre-market. While the market literally just opened, it looks like the stock is going to have a pretty impressive day. Below, we’ll talk about what we’re seeing from BCLI, why, and what we’ll be watching for ahead.





What We’re Seeing From BCLI

As mentioned above, the market just opened, but Brainstorm Cell Therapeutics is already having a pretty strong day. After a press release was offered, the stock skyrocketed in pre-market hours, leading to a strong head start on the day. At the moment (9:30), BCLI is trading at $3.63 per share after a gain of $0.21 per share or 6.14% thus far today.

Why The Stock Is Headed Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on BCLI. As soon as they did, the CNA Finance team started digging to see what was causing the movement. It didn’t take long to uncover the story. The gains are ultimately caused by a positive press release.




In the press release, Brainstorm Cell Therapeutics announced that it is planning on contracting with the City of Hope’s Center for Biomedicine and Genetics to produce clinical supplies of NurOwn(R) adult stem cells for an upcoming Phase 3 clinical study. In a statement, Dr. Joseph Gold, manufacturing director of City of Hope’s biological and cellular GMP manufacturing facility at the Center for Biomedicine and Genetics had the following to offer…

City of Hope is committed to the advancement of cellular therapy research and the treatment of serious disease that lack effective therapies.. We are pleased to support Brainstorm’s ALS clinical research program.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BCLI. In particular, we’ll be watching for further news surrounding the coming Phase 3 trial. Nonetheless, we’ll be watching the news closely and we’ll be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 501
Cytori Therapeutics Inc CYTX Stock News

Cytori Therapeutics Inc (NASDAQ: CYTX)

Cytori Therapeutics has had an interesting day in the market today. At the open, the stock started movement to the green, but quickly found the red. However, as the trading session progressed, the stock started to run on a clear trend upward. Below, we’ll talk about what we’re seeing from CYTX, why, and what we’ll be watching for ahead.





What We’re Seeing From CYTX

As mentioned above, Cytori Therapeutics is having a pretty strong day in the market today. While the stock was struggling to find a direction early on, that direction became defined in a big way as the afternoon started to roll in. Now, the stock is trading on some pretty impressive gains. Currently (3:38), CYTX is trading at $2.03 per share after a gain of $0.06 per share or 2.81% thus far today.

Why The Stock Is Having Such A Strong Day

As is just about always the case, our partners at Trade Ideas were the first to inform us of the gains on CYTX. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take very long to dig up the story. The gains are the result of investor excitement surrounding a price target increase.




Early today, analysts at Maxim weighed in on Cytori Therapeutics. In the report, it was announced that the analyst has nearly doubled the price target on the stock; bringing it from $6.00 to $10.00. This is incredible news as it insinuates a massive upside potential from the current price. In fact, it suggests that the stock will grow by about five times.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CYTX. In particular, we’re watching for further news with regard to the company’s pipeline and progress. Of course, we will watch for any other breaking stories as well. As always, as the news breaks, we’ll bring it to you!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 2069
Editas Medicine Inc EDIT Stock News

Editas Medicine Inc (NASDAQ: EDIT)

Editas Medicine was having a relatively normal day in the market. After starting the day off in the red, the stock quickly found its way to the green. From there, we’ve seen quite a bit of movement both above and below the line. However, minutes ago, things got interesting as the stock started to soar. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to EDIT ahead.





What We’re Seeing From EDIT

As mentioned above, Editas Medicine was off to what was a normal day in the market early on today. While the stock was in the red early on, it wasn’t down by much. Throughout the day, the stock stayed close to the breakeven point, spending some time both above and below the line. However, minutes ago, the stock started to soar as a court ruling came down the wire. At the moment (12:57), EDIT is trading at $21.78 per share after a gain of $2.92 per share (15.47%) thus far today.

Why The Stock Is Climbing

As is almost always the case, our partners at Trade Ideas were the first to send us the alert that EDIT is headed upward. As soon as we received the notification, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to find the court ruling that seems to be the cause of the run.




Minutes ago, a ruling started to come down the wire surrounding CRISPR patents held by Broad Institute. The ruling was that the patents would remain as they are. This is great news for Editas Medicine, as the company holds the exclusive license on applications of Zhang’s CRISPR-Cas9. Ultimately, the ruling held up the companies rights to the intellectual property.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EDIT. In particular, we’ll be watching the company’s ongoing work surrounding the disputed product. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 814
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...